Search for Clinical Trial Results
Amyloid Neuropathies - 47 Studies Found
Status | Study |
Completed |
Study Name: An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy Condition:
Date: 2008-11-13 Interventions: Drug: Fx-1006A Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each |
Completed |
Study Name: The Effect of Diflunisal on Familial Amyloidosis Condition:
Date: 2006-02-21 Interventions:
|
Completed |
Study Name: The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant Condition:
Interventions: Drug: Revusiran (ALN-TTRSC) 500mg Revusiran by subcutaneous (sc) injection |
Active, not recruiting |
Study Name: APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis Condition:
|
Available |
Study Name: Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR) Condition:
|
Completed |
Study Name: The Effect of Diflunisal on Familial Transthyretin Amyloidosis Condition: Amyloidosis Date: 2011-09-09 Interventions: Drug: Diflunisal Film-coated tablet, 250 mg twice daily, orally for approximately 2 years |
Completed |
Study Name: Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis Condition: Transthyretin Amyloidosis Date: 2010-07-27 Interventions: Drug: Doxycycline + Tauroursodeoxycholic acid doxycycline 100 mg twice a day for 12 months; tauroursodeo |
Recruiting |
Study Name: Transthyretin-Associated Amyloidoses Outcome Survey (THAOS) Condition:
Date: 2008-02-25 Interventions: Other: None. Observational Study. |
Completed |
Study Name: ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) Condition:
|
Completed |
Study Name: The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis Condition: Transthyretin-associated Amyloidosis With Polyneuropathy Date: 2008-02-27 Interventions: Drug: Fx-1006A During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at t |